HomeCompareIVMED vs SBUX

IVMED vs SBUX: Dividend Comparison 2026

IVMED yields 285714.29% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IVMED wins by $1.734986541242196e+31M in total portfolio value
10 years
IVMED
IVMED
● Live price
285714.29%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.734986541242196e+31M
Annual income
$17,337,928,197,276,910,000,000,000,000,000,000,000.00
Full IVMED calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — IVMED vs SBUX

📍 IVMED pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIVMEDSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IVMED + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IVMED pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IVMED
Annual income on $10K today (after 15% tax)
$24,285,714.29/yr
After 10yr DRIP, annual income (after tax)
$14,737,238,967,685,373,000,000,000,000,000,000,000.00/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, IVMED beats the other by $14,737,238,967,685,373,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IVMED + SBUX for your $10,000?

IVMED: 50%SBUX: 50%
100% SBUX50/50100% IVMED
Portfolio after 10yr
$8.67493270621098e+30M
Annual income
$8,668,964,098,638,455,000,000,000,000,000,000,000.00/yr
Blended yield
99.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

IVMED
No analyst data
Altman Z
-205.3
Piotroski
2/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IVMED buys
0
SBUX buys
0
No recent congressional trades found for IVMED or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIVMEDSBUX
Forward yield285714.29%2.75%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$1.734986541242196e+31M$157.5K
Annual income after 10y$17,337,928,197,276,910,000,000,000,000,000,000,000.00$65,840.13
Total dividends collected$1.734908400352195e+31M$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: IVMED vs SBUX ($10,000, DRIP)

YearIVMED PortfolioIVMED Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$28,582,129$28,571,428.57$11,107$407.21+$28.57MIVMED
2$76,351,353,429$76,320,770,551.21$12,512$626.87+$76351.34MIVMED
3$190,619,493,207,524$190,537,797,259,355.30$14,366$978.69+$190619493.19MIVMED
4$444,781,927,427,195,200$444,577,964,569,463,100.00$16,929$1,557.50+$444781927427.18MIVMED
5$969,967,353,346,567,200,000$969,491,436,684,220,000,000.00$20,658$2,543.80+$969967353346567.13MIVMED
6$1,976,961,629,315,093,000,000,000$1,975,923,764,247,012,300,000,000.00$26,406$4,302.22+$1976961629315092992.00MIVMED
7$3,765,923,944,594,039,000,000,000,000$3,763,808,595,650,671,000,000,000,000.00$35,877$7,622.00+$3.765923944594039e+21MIVMED
8$6,704,681,437,057,684,000,000,000,000,000$6,700,651,898,436,968,000,000,000,000,000.00$52,741$14,352.64+$6.704681437057683e+24MIVMED
9$11,156,275,836,497,016,000,000,000,000,000,000$11,149,101,827,359,364,000,000,000,000,000,000.00$85,676$29,243.03+$1.1156275836497015e+28MIVMED
10$17,349,865,412,421,960,000,000,000,000,000,000,000$17,337,928,197,276,910,000,000,000,000,000,000,000.00$157,513$65,840.13+$1.734986541242196e+31MIVMED

IVMED vs SBUX: Complete Analysis 2026

IVMEDStock

Whitebeard Inc., a development stage company, engages in the research and development of medical devices with `near-patient' testing applications. Its primary product includes prothrombin monitor, which is used for the measurement of coagulation of blood in patients at risk of heart disease and stroke. The company's other products under development include predictor of labor onset, a consumer device for maternity planning; biomarker monitor for the measurement of a number of biomarkers, including heart attack, HIV, cholesterol, and cancer; blood glucose monitor, a noninvasive glucose concentration continuous bulk measuring device measurement; digital scanning machine, a noninvasive alternative to 2D X-ray scanning; osteoporosis detection and monitoring device, an instant display of bonemineral density for osteoporosis patients; and hand held digital strip reader for immunoassay applications. It was formerly known as In Vivo Medical Diagnostics, Inc. and changed its name to In Veritas Medical Diagnostics, Inc. in 2005. The company is based in Inverness, the United Kingdom.

Full IVMED Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this IVMED vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IVMED vs SCHDIVMED vs JEPIIVMED vs OIVMED vs KOIVMED vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.